CALDER_PHARMACY_LIMITED - Accounts

Company Registration No. SC268645 (Scotland)
CALDER PHARMACY LIMITED
UNAUDITED FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2017
PAGES FOR FILING WITH REGISTRAR
CALDER PHARMACY LIMITED
COMPANY INFORMATION
Director
Mr C  Shanks
Secretary
Ms D Holmes
Company number
SC268645
Registered office
18 Calder Park
Edinburgh
EH11 4JN
Accountants
Geoghegans Accountancy Limited
Chartered Accountants
6 St Colme Street
Edinburgh
EH3 6AD
CALDER PHARMACY LIMITED
CONTENTS
Page
Balance sheet
1 - 2
Statement of changes in equity
3
Notes to the financial statements
4 - 10
CALDER PHARMACY LIMITED
BALANCE SHEET
AS AT
31 AUGUST 2017
31 August 2017
- 1 -
2017
2016
as restated
Notes
£
£
£
£
Fixed assets
Intangible assets
102,200
116,800
Tangible assets
4
7,061
7,407
Investment properties
5
321,904
-
Investments
6
20,775
20,500
451,940
144,707
Current assets
Stocks
19,529
18,742
Debtors
7
282,484
368,451
Cash at bank and in hand
122,791
157,306
424,804
544,499
Creditors: amounts falling due within one year
8
(84,455)
(178,137)
Net current assets
340,349
366,362
Total assets less current liabilities
792,289
511,069
Creditors: amounts falling due after more than one year
9
(251,849)
(79,701)
Provisions for liabilities
(1,023)
(1,104)
Net assets
539,417
430,264
Capital and reserves
Called up share capital
10
1,000
1,000
Profit and loss reserves (non-distributable)
1,225
950
Profit and loss reserves
537,192
428,314
Total equity
539,417
430,264

The director of the company has elected not to include a copy of the profit and loss account within the financial statements.true

For the financial year ended 31 August 2017 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

The members have not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476.

CALDER PHARMACY LIMITED
BALANCE SHEET (CONTINUED)
AS AT
31 AUGUST 2017
31 August 2017
- 2 -

These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and signed by the director and authorised for issue on 8 February 2018
Mr C  Shanks
Director
Company Registration No. SC268645
CALDER PHARMACY LIMITED
STATEMENT OF CHANGES IN EQUITY
FOR THE YEAR ENDED 31 AUGUST 2017
- 3 -
Share capital
Other reserves
Profit and loss reserves
Total
Notes
£
£
£
£
Balance at 1 September 2015
1,000
-
365,624
366,624
Year ended 31 August 2016:
Profit and total comprehensive income for the year
-
-
153,640
153,640
Dividends
-
-
(90,000)
(90,000)
Transfers
-
950
(950)
-
Balance at 31 August 2016
1,000
950
428,314
430,264
Year ended 31 August 2017:
Profit and total comprehensive income for the year
-
-
200,153
200,153
Dividends
-
-
(91,000)
(91,000)
Transfers
-
275
(275)
-
Balance at 31 August 2017
1,000
1,225
537,192
539,417
CALDER PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 31 AUGUST 2017
- 4 -
1
Accounting policies
Company information

Calder Pharmacy Limited is a private company limited by shares incorporated in Scotland. The registered office is 18 Calder Park, Edinburgh, EH11 4JN.

1.1
Accounting convention

These financial statements have been prepared in accordance with FRS 102 “The Financial Reporting Standard applicable in the UK and Republic of Ireland” (“FRS 102”) and the requirements of the Companies Act 2006 as applicable to companies subject to the small companies regime. The disclosure requirements of section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The financial statements are prepared in sterling, which is the functional currency of the company. Monetary amounts in these financial statements are rounded to the nearest £.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

These financial statements for the year ended 31 August 2017 are the first financial statements of Calder Pharmacy Limited prepared in accordance with FRS 102, The Financial Reporting Standard applicable in the UK and Republic of Ireland. The date of transition to FRS 102 was 1 September 2015. An explanation of how transition to FRS 102 has affected the reported financial position and financial performance is given in note 12.

1.2
Turnover

Turnover is recognised at the fair value of the consideration received or receivable for goods and services provided in the normal course of business, and is shown net of VAT.

1.3
Intangible fixed assets - goodwill

Goodwill represents the excess of the cost of acquisition of unincorporated businesses over the fair value of net assets acquired. It is initially recognised as an asset at cost and is subsequently measured at cost less accumulated amortisation and accumulated impairment losses. Goodwill is considered to have a finite useful life and is amortised on a systematic basis over its expected life, which is 20 years.

1.4
Tangible fixed assets

Tangible fixed assets are initially measured at cost and subsequently measured at cost or valuation, net of depreciation and any impairment losses.

Depreciation is recognised so as to write off the cost or valuation of assets less their residual values over their useful lives on the following bases:

Fixtures, fittings & equipment
15% on reducing balance

The gain or loss arising on the disposal of an asset is determined as the difference between the sale proceeds and the carrying value of the asset, and is credited or charged to profit or loss.

CALDER PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2017
1
Accounting policies
(Continued)
- 5 -
1.5
Investment properties

Investment property, which is property held to earn rentals and/or for capital appreciation, is initially recognised at cost, which includes the purchase cost and any directly attributable expenditure. Subsequently it is measured at fair value at the reporting end date. The surplus or deficit on revaluation is recognised in the profit and loss account.

 

Where fair value cannot be achieved without undue cost or effort, investment property is accounted for as tangible fixed assets.

1.6
Impairment of fixed assets

The carrying value of tangible fixed assets are reviewed for impairment when events or changes in circumstances indicate that the carrying value may not be recoverable.

1.7
Stocks

Stocks are stated at the lower of cost and net realisable value after making due allowance for obsolete and slow moving items. Cost is determined on a first-in. first-out basis. Net realisable value is based on estimated selling price, less any further costs of realisation.

1.8
Cash at bank and in hand

Cash at bank and in hand are basic financial assets and include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

1.9
Financial instruments

The company has elected to apply the provisions of Section 11 ‘Basic Financial Instruments’ and Section 12 ‘Other Financial Instruments Issues’ of FRS 102 to all of its financial instruments.

 

Financial instruments are recognised in the company's balance sheet when the company becomes party to the contractual provisions of the instrument.

 

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

Debtors

Debtors with no stated interest rate or receivable within one year are recorded at transaction price. Any losses arising from impairment are recognised in the profit and loss account.

Creditors

Creditors with no stated interest rate and payable within one year are recorded at transaction price.

 

All interest bearing loans and borrowings which are basic financial instruments are initially recorded at the present value of cash payable. After initial recognition they are measured at amortised cost.

 

1.10
Equity instruments

Equity instruments issued by the company are recorded at the proceeds received, net of direct issue costs. Dividends payable on equity instruments are recognised as liabilities once they are no longer at the discretion of the company.

1.11
Taxation

The tax expense represents the sum of the tax currently payable and deferred tax.

CALDER PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2017
1
Accounting policies
(Continued)
- 6 -
Current tax

The tax currently payable is based on taxable profit for the year. Taxable profit differs from net profit as reported in the profit and loss account because it excludes items of income or expense that are taxable or deductible in other years and it further excludes items that are never taxable or deductible. The company’s liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the reporting end date.

Deferred tax

Deferred tax liabilities are generally recognised for all timing differences and deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Such assets and liabilities are not recognised if the timing difference arises from goodwill or from the initial recognition of other assets and liabilities in a transaction that affects neither the tax profit nor the accounting profit.

 

The carrying amount of deferred tax assets is reviewed at each reporting end date and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered. Deferred tax is calculated at the tax rates that are expected to apply in the period when the liability is settled or the asset is realised. Deferred tax is charged or credited in the profit and loss account, except when it relates to items charged or credited directly to equity, in which case the deferred tax is also dealt with in equity. Deferred tax assets and liabilities are offset when the company has a legally enforceable right to offset current tax assets and liabilities and the deferred tax assets and liabilities relate to taxes levied by the same tax authority.

1.12
Employee benefits

The costs of short-term employee benefits are recognised as a liability and an expense, unless those costs are required to be recognised as part of the cost of stock or fixed assets.

 

The cost of any unused holiday entitlement is recognised in the period in which the employee’s services are received.

 

Termination benefits are recognised immediately as an expense when the company is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

1.13
Retirement benefits

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

1.14
Leases

Rental income from operating leases is recognised on a straight line basis over the term of the relevant lease. Initial direct costs incurred in negotiating and arranging an operating lease are added to the carrying amount of the leased asset and recognised on a straight line basis over the lease term.

2
Employees

The average monthly number of persons (including directors) employed by the company during the year was 6 (2016 - 9).

CALDER PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2017
- 7 -
3
Intangible fixed assets
Goodwill
£
Cost
At 1 September 2016 and 31 August 2017
292,000
Amortisation and impairment
At 1 September 2016
175,200
Amortisation charged for the year
14,600
At 31 August 2017
189,800
Carrying amount
At 31 August 2017
102,200
At 31 August 2016
116,800
4
Tangible fixed assets
Plant and machinery etc
£
Cost
At 1 September 2016
29,094
Additions
802
At 31 August 2017
29,896
Depreciation and impairment
At 1 September 2016
21,687
Depreciation charged in the year
1,148
At 31 August 2017
22,835
Carrying amount
At 31 August 2017
7,061
At 31 August 2016
7,407
5
Investment property
2017
£
Fair value
At 1 September 2016
-
Additions
321,904
At 31 August 2017
321,904
CALDER PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2017
5
Investment property
(Continued)
- 8 -

Investment property comprises two properties held to earn rental income.

6
Fixed asset investments
2017
2016
£
£
Investments
20,775
20,500
Movements in fixed asset investments
Investments other than loans
£
Cost or valuation
At 1 September 2016
20,500
Valuation changes
275
At 31 August 2017
20,775
Carrying amount
At 31 August 2017
20,775
At 31 August 2016
20,500
7
Debtors
2017
2016
Amounts falling due within one year:
£
£
Trade debtors
64,826
117,468
Other debtors
217,658
250,983
282,484
368,451
8
Creditors: amounts falling due within one year
2017
2016
£
£
Bank loans and overdrafts
31,813
4,860
Trade creditors
33,837
145,747
Corporation tax, other taxation and social security
15,523
26,237
Other creditors
3,282
1,293
84,455
178,137
CALDER PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2017
- 9 -
9
Creditors: amounts falling due after more than one year
2017
2016
£
£
Bank loans and overdrafts
251,849
79,701

The aggregate amount of creditors for which security has been given amounted to £283,662 (2016 - £84,557).

 

The Royal Bank of Scotland PLC has a bond and floating charge over the undertaking and all property and assets present and future.

 

The Royal Bank of Scotland PLC holds a fixed charge over the property at Leyland Road and another over the property at Sighthill Park.

10
Called up share capital
2017
2016
£
£
Ordinary share capital
Issued and fully paid
1,000 Ordinary Shares of £1 each
1,000
1,000
1,000
1,000
11
Related party transactions

Included in other debtors is a balance of £164,227 (2016: £184,400) owed by Mr C Shanks, director of the company. Interest is charged at 4%. Of this balance, £160,000 is considered to be long term in nature.

12
Reconciliations on adoption of FRS 102
Reconciliation of equity
At 1 September 2015
At 31 August 2016
Previous UK GAAP
Effect of
transition
FRS 102
Previous UK GAAP
Effect of
transition
FRS 102
Notes
£
£
£
£
£
£
Capital and reserves
Share capital
1,000
-
1,000
1,000
-
1,000
Revaluation reserve
a)
-
-
-
950
(950)
-
Other reserves
a)
-
-
-
-
950
950
Profit and loss
365,624
-
365,624
428,314
-
428,314
Total equity
366,624
-
366,624
430,264
-
430,264
CALDER PHARMACY LIMITED
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)
FOR THE YEAR ENDED 31 AUGUST 2017
12
Reconciliations on adoption of FRS 102
(Continued)
- 10 -
Reconciliation of profit for the financial period
Year ended 31 August 2016
Previous UK GAAP
Effect of
transition
FRS 102
Notes
£
£
£
Profit for the financial period
a)
152,690
950
153,640
Notes to reconciliations on adoption of FRS 102
a) Movement of revaluation reserve to non-distributable reserves

Following the transition to FRS102, the revaluation reserve has been transferred to a non-distributable reserves category. This has resulted in an adjustment between the revaluation reserve and non-distributable profit and loss reserve of £950.

2017-08-312016-09-01falseCCH SoftwareCCH Accounts Production 2017.300No description of principal activity08 February 2018SC2686452016-09-012017-08-31SC268645bus:Director12016-09-012017-08-31SC268645bus:CompanySecretary12016-09-012017-08-31SC268645bus:RegisteredOffice2016-09-012017-08-31SC2686452017-08-31SC2686452016-08-31SC268645core:NetGoodwill2017-08-31SC268645core:NetGoodwill2016-08-31SC268645core:OtherPropertyPlantEquipment2017-08-31SC268645core:OtherPropertyPlantEquipment2016-08-31SC268645core:CurrentFinancialInstruments2017-08-31SC268645core:CurrentFinancialInstruments2016-08-31SC268645core:Non-currentFinancialInstruments2017-08-31SC268645core:Non-currentFinancialInstruments2016-08-31SC268645core:ShareCapital2017-08-31SC268645core:ShareCapital2016-08-31SC268645core:OtherMiscellaneousReserve2017-08-31SC268645core:OtherMiscellaneousReserve2016-08-31SC268645core:RetainedEarningsAccumulatedLosses2017-08-31SC268645core:RetainedEarningsAccumulatedLosses2016-08-31SC268645core:ShareCapitalcore:RestatedAmount2015-08-31SC268645core:RetainedEarningsAccumulatedLossescore:RestatedAmount2015-08-31SC268645core:RestatedAmount2015-08-31SC268645core:ShareCapitalOrdinaryShares2017-08-31SC268645core:ShareCapitalOrdinaryShares2016-08-31SC2686452015-09-012016-08-31SC268645core:RetainedEarningsAccumulatedLosses2015-09-012016-08-31SC268645core:Goodwill2016-09-012017-08-31SC268645core:FurnitureFittings2016-09-012017-08-31SC268645core:NetGoodwill2016-08-31SC268645core:NetGoodwill2016-09-012017-08-31SC268645core:OtherPropertyPlantEquipment2016-08-31SC268645core:OtherPropertyPlantEquipment2016-09-012017-08-31SC268645bus:OrdinaryShareClass12016-09-012017-08-31SC268645bus:OrdinaryShareClass12017-08-31SC268645bus:PrivateLimitedCompanyLtd2016-09-012017-08-31SC268645bus:FRS1022016-09-012017-08-31SC268645bus:AuditExemptWithAccountantsReport2016-09-012017-08-31SC268645bus:SmallCompaniesRegimeForAccounts2016-09-012017-08-31SC268645bus:FullAccounts2016-09-012017-08-31xbrli:purexbrli:sharesiso4217:GBP